You are here: Industry Insights > Dicerna

News List

Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement americanpharmaceuticalreview
May 25, 2021
Dicerna announced that Boehringer Ingelheim has accepted a GalXC™ RNAi candidate for advancement under the existing agreement between the companies for the discovery and development of novel therapies for the treatment of chronic liver diseases.
EC grants orphan drug status to Dicerna’s DCR-A1AT to treat congenital A1AT deficiency pharmaceutical-business-review
December 20, 2019
Dicerna Pharmaceuticals has secured orphan drug designation from the European Commission (EC) for its DCR-A1AT to treat congenital alpha-1 antitrypsin (A1AT) deficiency.
Alexion joins with Dicerna to develop RNAi therapies for complement diseases pharmaphorum
December 20, 2018
Alexion has announced a collaboration with Dicerna Pharmaceuticals to discover and develop RNA interference therapies for diseases caused by problems in the complement system.
Dicerna agrees another gene-silencing deal, this time with Lilly pharmaphorum
December 18, 2018
Eli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake in the RNA interference specialist.
Boehringer, Dicerna pen $201M pact to hit NASH with RNAi fiercebiotech
November 03, 2017
Boehringer Ingelheim has put up $201 million (€173 million) to work with Dicerna Pharmaceuticals on RNAi treatments for NASH and other chronic liver diseases.